Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Eye Care

Journal Scan / Research · August 24, 2020

Risk of Systemic Adverse Events Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept

Ophthalmology

 

Additional Info

Ophthalmology
Risk of Systemic Adverse Events Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice
Ophthalmology 2020 Aug 08;[EPub Ahead of Print], MH Maloney, SR Payne, J Herrin, LR Sangaralingham, ND Shah, AJ Barkmeier

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading